Date: Sat 3 Nov 2018
Source: Ghana Web [edited]
<https://www.ghanaweb.com/GhanaHomePage/health/Doctors-announce-Apollo-outbreak-in-Tamale-697640>

A new surge of the contagious viral eye disease known [locally] as "apollo" or haemorrhagic conjunctivitis has been confirmed by doctors at the Tamale Central Hospital in the northern regional capital. Apollo is an infection caused by the Coxsackie virus and presents with painful swollen red eyes, purulent discharges and headache, and affects the lining of the eyelids and eyeball. It usually affects both eyes but may affect one eye and later spread to the other. The disease affects people of all ages, particularly those in crowded living conditions (i.e., homes, schools, daycare centres, and work places) and those who engage in poor handwashing practices.

Apollo is spread by contact with the hands, towels, face cloths, goggles and other surfaces exposed to secretions that contain the virus. The symptoms of apollo include sore eyes, feeling of grittiness or burning, redness, watery discharge, swelling of eyelids and light sensitivity. The disease has damaged eyes of many people since its last outbreak 7 years ago in the country. A report of the outbreak has been issued by the senior optometrist of the hospital, Dr. Daniel Opoku, to the National Health Directorate in the region. The report said the hospital had received an increasing number of cases of the disease since last month [October 2018], without specifying a figure.

The statement also confirms some of the hospital staff have been affected in the outbreak and have been asked to visit the eye clinic for treatment. The hospital staff have been cautioned to be careful in their contact with patients and their folders. The staff have also been advised to practice proper hand hygiene to avoid being infected. The Ophthalmological Society of Ghana (OSG) in the region has not commented on the report, and there have not been any comments from the Red Cross Society. The Regional Health Service has confirmed the report but said the situation is being contained.
===========================
[Acute haemorrhagic conjunctivitis (AHC) was 1st described in Ghana in 1969 [1]. Its appearance coincided with the 1st Apollo moon landing, prompting the Ghanaians to give it the name Apollo 11 disease [2]. The etiological agent in this outbreak was identified as enterovirus 70 (EV70) [2, 3]. In the following year [1970], an outbreak of apollo was described in Singapore [4]; however, in this case, the cause was determined to be a Coxsackie virus A24 variant (CVA24v) [5].

Since then, numerous reports of AHC have emerged from across the world, associated with either EV70 or CVA24v. These 2 viruses are now recognized as the primary agents of AHC [6]. ... AHC usually resolves without sequelae, although secondary corneal infection has been reported after treatment with topical steroids [8].

References
1. Chatterjee S, Quarcoopome CO, Apenteng A. Unusual type of epidemic conjunctivitis in Ghana. Br J Ophthal 1970;54:628-630.
2. Kono R. Apollo 11 disease or acute hemorrhagic conjunctivitis: a pandemic of a new enterovirus infection of the eyes. Am J Epidemiol 1975;101:383-390.
3. Mirkovic RR, Kono R, Yin-Murphy M, et al. Enterovirus type 70: the etiologic agent of pandemic acute haemorrhagic conjunctivitis. Bull World Health Org 1973;49:341-346.
4. Mirkovic RR, Schmidt NJ, Yin-Murphy M, Melnick JL. Enterovirus etiology of the 1970 Singapore epidemic of acute conjunctivitis. Intervirology A 1974;4:119-127.
5. Line KH, Yin-Murphy M. An epidemic of conjunctivitis in Singapore in 1970. Singapore Med J 1971;12:247-249.
6. Wright PW, Strausss GH, Langford MP. Acute hemorrhagic conjunctivitis. Am Fam Phys 1992;45:173-178. …
8. Vajpayee RB, Sharma N, Chand M, et al. Corneal superinfection in acute hemorrhagic conjunctivitis. Cornea 1998;6:614-617. Excerpted from Burr SE, Sillah, Joof H, et al. An outbreak of acute haemorrhagic conjunctivitis associated with coxsackievirus A24 variant in The Gambia, West Africa. BMC Res Notes 2017;10:692. - ProMED Mod.LK]
 
[HealthMap/ProMED-mail map:
Ghana: <http://healthmap.org/promed/p/53>]
Date: Thu, 20 Sep 2018 22:11:23 +0200

Accra, Sept 20, 2018 (AFP) - At least 34 people have died in northern Ghana during flooding caused by heavy rains and waters spilling from a dam in neighbouring Burkina Faso, relief agency officials said Thursday.   Bagre Dam is located on the White Volta river that begins in Burkina Faso and which converges with the Black Volta downstream and feeds into Lake Volta in southern Ghana.  The authorities open the dam's spillways during annual rains, but the excess volumes of water regularly flood communities along the rivers.

People living along the White Volta have been urged to stay away from its banks.Others have been told to move to higher ground.   Seji Saji, deputy head of Ghana's National Disaster Management Organisation, said the situation was under control and teams were working flat out to reach those affected.   "In all we have on record 34 deaths and two people missing. The affected people are over 52,000 and we are still assessing the situation," he added.   "All these happened during the time that the river overflowed its banks but the rate of spillage has reduced considerably and fortunately since last week and this week there has not been any heavy rainfall."

Ghana's President Nana Akufo-Addo and his government have been criticised for not visiting victims of the floods.  Aid agency Oxfam's inequality programmes and campaign manager in Ghana, Zakaria Sulemana, said the situation required "high-powered political attention".   "People want to hear the president, in fact we should have seen the president visit the area to console them or better still initiate an action to ensure that this does not happen again," he added.   Saji said Vice-President Mahamudu Bawumia will be visiting flood victims this weekend.   In 1999, flooding in the Upper West, Upper East, Northern and Brong Ahafo and Volta regions of northern Ghana affected more than 300,000 people, according to NADMO.
Date: Wed 13 Jun 2018
Source: WHO, Regional Office for Africa [edited]
<http://www.afro.who.int/news/ghana-eliminates-trachoma-freeing-millions-suffering-and-blindness>

The World Health Organization (WHO) today [Wed 13 Jun 2018] congratulated Ghana for having eliminated trachoma as a public health problem, 2 decades after the World Health Assembly resolved to tackle the leading infectious cause of blindness. The announcement comes the day after a commitment from Pfizer, the manufacturer of Zithromax (azithromycin) to extend their donation programme for the antibiotic until 2025, if required, to finish the task of global trachoma elimination.

"It's been 20 years since the global health community committed to eliminating trachoma worldwide" said WHO Director-General, Dr. Tedros Adhanom Ghebreyesus. "Although there's more work to do elsewhere, the validation of elimination in Ghana allows another previously heavily-endemic country to celebrate significant success."

Ghana is the 1st country in WHO's African Region to achieve this milestone.

"This success is a result of a tremendous amount of hard work by thousands of health, education and development workers to improve the lives of individuals with trachoma and their families", said Mr. Kwaku Agyemang-Manu, Ghana's Minister of Health. "The Government of Ghana is enormously grateful to its staff and to the many partners that have joined forces with us to eliminate trachoma and the cycle of poverty it triggers."

The global trachoma community learnt a lot from Ghana's experience. Innovations pioneered there include the use of height-based dosing for azithromycin; systematic active case-searches for trichiasis involving door-to-door, community-by-community fieldwork; and, intensive counseling of patients found to have trichiasis with an offer of immediate surgery, which produced considerable improvement in surgical uptake.

"Success in Ghana is a result of the strong leadership at all levels, implementation of the full SAFE strategy right from the outset, strong collaboration between Ghana Health Service and its many partners, and integration at lower levels of programme delivery, including community ownership," said Dr. Matshidiso Moeti, WHO Regional Director for Africa. "Hearty congratulations are deserved for this achievement."

Trachoma: Ghana's story
-----------------------
Trachoma was identified in the 1950s as the most important cause of blindness in Ghana. By the 1990s, the disease was known to persist as a significant public health problem in the Northern and Upper West Regions. There were about 2.8 million people at risk of trachomatous blindness nationally, with an estimated 13 000 people suffering from trichiasis. In 2000, the Ministry of Health and Ghana Health Service set up a national Trachoma Elimination Programme.

Ghana's Trachoma Elimination Programme implemented the WHO-recommended elimination strategy, SAFE, which comprises Surgery for trichiasis, Antibiotics to clear infection, Facial cleanliness, and Environmental improvement to reduce transmission.

Trichiasis surgery was provided at no cost, a critical Ghana Health Service decision reflecting the socioeconomic disadvantage of people with trichiasis and the impact of the condition on future earning potential.

Azithromycin, donated by Pfizer through the International Trachoma Initiative, was distributed with support from FHI 360 (using funds from the United States Agency for International Development), The Carter Center, Sightsavers and other organizations.

Facial cleanliness was promoted through community events, dramas, the school health education programme, radio messages and radio clubs. Environmental improvement was coordinated by Ghana's Community Water and Sanitation Agency.

The disease
-----------
Trachoma, a devastating eye disease caused by infection with the bacterium _Chlamydia trachomatis_, is spread through contact with infective eye or nose discharges, either directly from person to person, or mediated by flies. Active (inflammatory) trachoma occurs as a result of infection, and is common among preschool-aged children. Women are blinded up to 4 times as often as men, mainly due to their close contact with infected children. Transmission is associated with poor sanitation and hygiene, which increase the availability of eye discharges and encourage the breeding of flies.

GET2020
-------
In 1996, WHO launched the WHO Alliance for the Global Elimination of Trachoma by the year 2020 (GET2020). With other partners in the Alliance, WHO supports country implementation of the SAFE strategy and strengthening of national capacity through epidemiological assessment, monitoring, surveillance, project evaluation and resource mobilization. Elimination of trachoma is inexpensive, simple and extremely cost effective, yielding a high rate of net economic return.
------------------------------------------
Communicated by:
Dr. Anthony Solomon MBBS, DTM&H, PhD, PGCAP, FHEA, FRCP
Medical Officer, Neglected Tropical Diseases
Department of Control of Neglected Tropical Diseases
World Health Organization
Switzerland
solomona@who.int
========================
[ProMED-mail thanks Dr. Anthony Solomon for this submission. Dr. Solomon comments: "I'm delighted to share news of the validation of elimination of trachoma in Ghana - the 1st country in WHO's African Region to reach this mark."

For a discussion of trachoma, please see my moderator comments in a prior ProMED-mail post Trachoma - Nepal: WHO, eliminated as a public health problem http://promedmail.org/post/20180522.5810321.

HealthMap/ProMED-mail map of Ghana can be seen at
<http://healthmap.org/promed/p/53>. - ProMED Mod.ML]
Date: Tue, 15 May 2018 12:48:37 +0200
By Stacey KNOTT

Obuasi, Ghana, May 15, 2018 (AFP) - Bismark Owusu moves food and bowls from a bedroom and covers clothes and furniture with a large sheet before mixing a mosquito-killing chemical with water in his spray pack.   He then puts on head-to-toe safety gear, straps the pack to his back and methodically sprays the walls, windows and corners of the room.   Owusu's visit to Domeabra, a small community in the Obuasi area of the Ashanti region in central Ghana, is his latest stop in the country's fight against malaria.

The death of two of his friends from the disease spurs him on. "Why wouldn't I help if others are dying? I am here today helping to eradicate this deadly malaria," he told AFP.   Malaria, which is spread to people through the bites of infected female mosquitoes, is one of the world's deadliest diseases.   According to the World Health Organization, there were 216 million cases of malaria in 91 countries across the world in 2016 and 445,000 deaths.   Most of those cases and deaths  -- about 90 percent -- were in sub-Saharan Africa.

In Ghana, which is home to some 28 million people, there were 4.8 million cases and 599 deaths last year, a marked drop from the 2,200 who died in 2011.   But with global concern that the fight against malaria has reached a plateau, African governments and development agencies are looking at new ways to step up the fight.   That includes preventative measures such as distribution of insecticide-treated mosquito nets and developing a vaccine against the disease but also indoor spraying.   Ghana is the first on the continent to introduce the large-scale use of a new "third generation insecticide" against mosquitoes, which have developed a resistance to other chemicals.

- 'Intelligent insects' -
As Ghana's rainy season approaches, when malaria cases increase, Owusu and his colleagues at the non-profit organisation AGALMal are working flat out.   The organisation grew out of a social initiative by global mining firm AngloGold Ashanti and has a laboratory in the grounds of an old mining site in Obuasi.   There, tiny mosquito pupae dart around in water in a white plastic container in a lab. 

Soon they will transform into mosquitoes and be studied by scientists. Technologist Paul Osei-Bonsu said chemical resistance was a major issue for the spraying programme.   If a population of mosquitoes is sprayed and just one survives and reproduces, the resistance will be passed on, he explained.   "If you use the same spray over time you will have 90 percent of the population not dying," he added.

Programme director Samuel Asiedu says mosquitoes are "intelligent insects", so the new chemical -- SumiShield 50WG -- should be more effective when rotated with others.   In 2006, after the first two years of the indoor spraying, the hospital in Obuasi saw a 75-percent decrease in malaria cases.    That led to the programme being expanded with additional support from global health initiative Unitaid and the Global Fund partnership.

Currently, the indoor spraying programme targets the homes of 1.2 million people.   "We are anticipating other chemicals to come on board by the end of the year so we can be rotating the use of chemicals to prevent resistance development," said Asiedu.   Unitaid project director David McGuire said he hoped the scheme "will convince donors and national governments to increase their investment in this life-saving intervention".

- 'Peace of mind' -
Keziah Malm, who manages the national malaria control programme at the Ghana Health Service, says the new WHO-approved spray is considered safe and has been tested internationally and locally.   It will be used in Obuasi and Ghana's far north -- all of the Upper West region and three districts in the Upper East -- which are high-risk zones for malaria.

Local communities still need to be convinced about the benefits of having their homes sprayed. But Asiedu says only a handful of people refuse.   Sprayers themselves also speak to households about the work and the risks to health from the disease, which can lead to severe illness and death if not treated within 24 hours.   "If I go to the whole house and someone does not want it I have to sit the person and let them know the importance of the spraying because malaria kills," said Owusu.    "It's very important we all understand that malaria is a killer. We have to eradicate it and kick it out of Obuasi and the nation as a whole."

During the course of his work, he's found everyone has a story about the disease.   "I sprayed a full house and the owner was telling me her son died some years go from malaria. He would be 18 years today. She was crying bitterly," he added.   Children under five and pregnant women are considered most vulnerable to malaria.   Seamstress Victoria Awuah lives in an eight-room house some 30 minutes from the lab.   She is seven months pregnant and doesn't need much persuasion to have her room sprayed.   "The spraying really helps. It helps us so that we don't get sick, give us peace of mind and rid this area of all these insects," she added.
Date: Thu 1 Mar 2018
Source: Graphic Online [edited]
<https://www.graphic.com.gh/news/general-news/one-confirmed-dead-from-lassa-fever.html>

The Ghana Health Service (GHS) has confirmed the 1st recorded case of Lassa fever in the country at Tema General Hospital. Dr Anthony Nsiah-Asare, the director-general of the Ghana Health Service, who was speaking to the media in Accra on Thursday [1 Mar 2018], said one person has been confirmed dead from Lassa fever.

Lassa fever is transmitted to humans via contact with food or household items contaminated with the urine, saliva faeces, and blood of infected rodents.

The confirmation, Dr Nsiah-Asare said, followed a test conducted by the Noguchi Memorial Institute for Medical Research. He said that, currently, all the frontline staff at the hospital that handled the patient before he died were being screened, while further investigations to trace the background and all contacts of the deceased were being pursued to prevent the spread of the virus. He called on the public to be extremely cautious of rodents and maintain good hygiene. He also urged the public to report any suspected case of the disease.

The GHS in February 2018 issued an alert of the likelihood of an outbreak of Lassa fever in the country. The disease is said to have already affected several countries in West Africa with, over 300 cases and 31 deaths in Nigeria.

The GHS recommended the following to all health workers and institutions:

1. Surveillance on Lassa fever, and acute hemorrhagic fevers in general (using case definitions), should be enhanced.
2. Suspected cases of Lassa fever should be managed in specific isolation conditions.
3. Health workers should adhere to regular infection prevention and control (IPC) measures to prevent and protect against possible nosocomial transmission.
4. Blood samples from suspected case(s) should be taken and safely packaged and sent to Noguchi Memorial Institute for Medical Research (NMIMR) for laboratory investigations.
5. All levels (national, regional, districts and facilities) are requested to update their preparedness and response plans for Lassa fever and VHF in general, sensitize the respective staff, and create necessary public awareness.

Lassa fever [LF] is an acute viral haemorrhagic fever illness which is endemic in West Africa. The incubation period is 6-21 days. The onset of LF illness is often gradual, with non-specific signs and symptoms and commonly presents with fever, general weakness, and malaise at the early onset. After a few days, headache, sore throat, muscle pain, chest pain, vomiting, diarrhoea and abdominal pain may follow. Severe cases may progress to show facial swelling, and bleeding tendencies (from mouth, nose, vagina or gastrointestinal tract), and low blood pressure. Shock, seizures, disorientation, and coma may be seen in the late stages. Complications include: deafness, transient hair loss, and gait disturbance may occur during recovery. About 80 per cent of Lassa fever infections are mild or asymptomatic.

- Lassa fever virus is transmitted to humans via contact with food or household items contaminated with the urine, saliva faeces, and blood of the rodent (Multi-mammate rat).
- Person-to-person infections and laboratory transmission can also occur, particularly in hospitals lacking adequate infection prevent and control measures.
- The disease is endemic in the rodent population in parts of West Africa, and the multi-mammate rat serves as reservoir for the virus.
- Lassa fever is known to be endemic in Benin, Guinea, Liberia, Mali, Sierra Leone and parts of Nigeria, but probably exists in other West African countries as well.
- Ghana recorded the 1st confirmed case(s) in 2011 in 2 districts, one each in Ashanti and Eastern regions, then confirmed outbreaks of Lassa fever (see Lassa fever - Ghana: (AH, EP) susp. http://promedmail.org/post/20111220.3642).
- Early use of [Ribavirin] (within 7 days of disease onset), supportive care with re-hydration, and symptomatic treatment improve survival.
- There is no effective vaccine for the disease at the moment.  [byline: Seth J Bokpe]
======================
[Lassa fever has been active in several West African countries this year [2018], including Nigeria, Liberia ex Guinea, and Benin ex Nigeria, so it is not surprising that a case has been diagnosed in Ghana. Interestingly, this was predicted previously. In commenting on the 2011 cases in Ghana, the late Mod.CP commented that Lassa virus infection had not been recorded previously in Ghana, but the lesser prevalence of Lassa fever in Ghana was predicted by a spatial-climatic analysis of Lassa fever data from human cases and infected rodent hosts in West Africa during the period 1965-2007 (See Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis. 2009;3(3):e388) <http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000388;jsessionid=A18CA8161C084054F4225595CF9E71CB> and also the ProMED-mail archived report: Lassa fever, predictive maps - West Africa http://promedmail.org/post/20090428.1605).

Halting the acquisition of Lassa fever virus infection at its source -- at the village level -- is not easy. As noted previously, getting local people to understand that virus transmission to humans occurs when people are in contact with the reservoir rodent host, the multimammate mouse (in the genus _Mastomys_) or its excreta can be difficult. Preventing this contact requires understanding that leads to action. Rodent control and prevention of contact with rodent excreta have to be undertaken at the village level with individual households. This requires an extensive and continuous public education effort. Transmission of the virus also occurs in health facilities when personal protective equipment is not employed and barrier-nursing practices are not adequate to protect staff from blood and secretions of infected patients. Although no vaccine is available, Ribavirin has been used to successfully treat patients and is most effective if patients are treated early in the course of infection.

Images of the mastomys mouse, the rodent reservoir of Lassa fever virus, can be seen at
<https://www.inaturalist.org/taxa/45326-Mastomys-natalensis>. - ProMED Mod.TY]

[HealthMap/ProMED-mail map of Ghana:
<http://healthmap.org/promed/p/53>.]
More ...